EyePoint (EYPT) has just hit a key clinical milestone that puts fresh attention on its stock. The company completed enrollment ahead of schedule in its global Phase 3 COMO and CAPRI trials for DURAVYU in diabetic macular edema.

The DURAVYU update comes after a sharp 8.26% 1 day share price return and 13.39% 7 day share price return, although the share price is still down 20.54% year to date while the 1 year total shareholder return is 35.78%. This suggests recent momentum is rebuilding after earlier weakness.

If EyePoint's clinical progress has caught your attention, it could be a good moment to see what else is moving in healthcare by checking out 43 healthcare AI stocks

EyePoint now trades at US$13.89, while analyst targets cluster near US$40. The gap is wide after this clinical update, so where might a reasonable view of fair value fall between the current price and the estimate range?

Most Popular Narrative: 65.7% Undervalued

Against the latest price of $13.89, the most followed narrative for EyePoint points to a fair value near $40.54. This implies a large valuation gap based on long range trial and earnings assumptions.

Analysts are assuming EyePoint's revenue will grow by 259.6% annually over the next 3 years. Analysts are not forecasting that EyePoint will become profitable in the next 3 years. To represent the Analyst Price Target as a Future PE Valuation, we will estimate EyePoint's profit margin will increase from 3567.1% below break even to the average AU Pharmaceuticals industry of 19.7% in 3 years.

Want to understand why this narrative sees such a sharp shift from heavy losses to healthy margins? The story leans on rapid revenue expansion and a rich future earnings multiple. Curious which specific growth and profitability milestones sit behind that fair value line? The full narrative breaks down the model in detail.

Result: Fair Value of $40.54 (UNDERVALUED)

However, this upbeat EyePoint story still hinges on DURAVYU. Any setback in the Phase 3 program or slower than expected adoption could quickly challenge that undervalued narrative.

Another View on EyePoint's Valuation

The narrative and SWS DCF model both point to EyePoint looking cheap, with the stock at $13.89 and an estimated future cash flow value of $130.75. That is a very wide gap. If both are roughly right, how much risk are you willing to take on the path in between?

Next Steps

With EyePoint's story pulling in different directions, it makes sense to review the underlying numbers yourself and build your own conviction. If you want a quick snapshot of both sides of the argument, start by weighing up the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond EyePoint?

If EyePoint has sharpened your focus on opportunities, do not stop here. Use the Simply Wall St Screener to spot fresh ideas before the crowd catches on.

• Pinpoint potential bargains by zeroing in on companies that combine quality with attractive pricing using the 52 high quality undervalued stocks.
• Strengthen your income stream by checking stocks that feature reliable payouts through the 8 dividend fortresses.
• Dial back risk without stepping away from opportunity by reviewing the 83 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.